RecruitingNot ApplicableNCT06508567

Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era


Sponsor

University Health Network, Toronto

Enrollment

20 participants

Start Date

Aug 8, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.


Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a highly precise type of radiation treatment — MRI-guided high-dose-rate brachytherapy, where radioactive seeds are placed near the tumor — for men whose prostate cancer has come back in the prostate bed area after they previously received radiation therapy. **You may be eligible if...** - You are over 18 years old and have previously received radiation therapy to the prostate area - You have a confirmed recurrence of cancer in the prostate bed (confirmed by biopsy, MRI, or a specialized PSMA PET scan) - Your PSA level has risen on at least two consecutive tests and is above 0.2 ng/dL - Your PSA doubling time from its lowest point is more than 6 months - You are in good overall health (ECOG 0–2) **You may NOT be eligible if...** - Scans show that cancer has spread to distant parts of the body - You had severe bowel or urinary side effects from your previous radiation - You have contraindications to MRI (e.g., certain metal implants) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONHigh Dose Rate Brachytherapy

2 fractions of MRI-guided HDR Brachytherapy (13Gy each) delivered over 14 days (± 7 days).


Locations(1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06508567


Related Trials